ClinicalTrials.gg
TerminatedNCT04504916Updated Nov 10, 2025Results posted

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

A Phase 2 interventional study of Zilovertamab vedotin in Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer and NSCLC, sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). Terminated at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
Business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc — 3 open to participants now, 3 under way, 3 of them phase 3. Triple Negative Breast Neoplasms · Merck & Co., Inc.

Enrollment
11th of 17
102 · median 462
Started
2020
the only one that year
Phase 2
5 of 17
none open now
Registered
11th of 17
by date

Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, this one is the 11th largest by enrollment, is the only one that started in 2020, is one of 5 in phase 2, and was the 11th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

3 of the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%.

Read the detailed description

Participants enrolled prior to Amendment 3 will receive zilovertamab vedotin at 2.5 mg/kg given intravenously on Day 1 of repeated 21-day cycles. Participants enrolled after Amendment 3 will receive zilovertamab vedotin at 1.75 mg/kg given intravenously on Day 1 and Day 8 of repeated 21-day cycles. Treatment will continue until progressive disease or discontinuation.

03

Conditions studied

  • Triple-negative Breast Cancer
  • Non-squamous Non-small-cell Lung Cancer
  • NSCLC
  • Estrogen-receptor-positive Breast Cancer
  • Progesterone-receptor-positive Breast Cancer
  • Estrogen-receptor-negative Breast Cancer
  • ER-negative Breast Cancer
  • Progesterone-receptor Negative Breast Cancer
  • PR-negative Breast Cancer
  • HER2-negative Breast Cancer
  • ER-positive Breast Cancer
  • PR-positive Breast Cancer
  • Platinum-resistant Ovarian Cancer
  • Gastric Cancer
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC -negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, or platinum-resistant ovarian cancer.
  • Has disease that has progressed during or following previous treatment appropriate for the disease type
  • Presence of radiographically .
  • Is willing to provide tumor tissue
  • Has adequate organ function
  • Has a negative test or adequate therapy for (HIV), , and/or .
  • Has completed all prior therapy.
  • Female subjects of must have a negative serum pregnancy test.
  • Both male and female subjects must be willing to use adequate .

Exclusion criteria

Exclusion Criteria:

  • Has peripheral neuropathy of Grade >1.
  • Has a involving the central nervous system.
  • Has another major cancer.
  • Has an uncontrolled ongoing infection.
  • Has significant cardiovascular disease.
  • Has a known diagnosis of liver cirrhosis.
  • Is pregnant or breastfeeding.
  • Has had major surgery within 4 weeks before the start of study therapy.
  • Has known tumor resistance or intolerance to a prior MMAE-containing drug.
  • Is concurrently participating in another therapeutic or imaging clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Zilovertamab Vedotin

    Participants will receive intravenous (IV) zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W) or 1.75 mg/kg on Day 1 and Day 8 of each 21-day cycle (Q2/3W). Treatment will continue until progressive disease or discontinuation

    Drug: Zilovertamab vedotin

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)

    The percentage of participants who achieved a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) using per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 by BICR was reported.

    Time frame: Up to ~18 months

Secondary outcomes

  1. ORR- Investigator Assessed

    The percentage of participants who achieved a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST, Version 1.1 by investigator was reported.

    Time frame: Up to ~18 months

  2. Time to Response (TTR)- BICR

    TTR, defined as the time from the start of study treatment to the first documentation of objective tumor response per RECIST, Version 1.1 by BICR was reported.

    Time frame: Up to ~30 months

  3. Duration of Response (DOR)- BICR

    DOR, defined as the interval from the first documentation of objective tumor response to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.

    Time frame: Up to ~30 months

  4. Progression-free Survival (PFS)- BICR

    PFS, defined as the interval from the start of study treatment to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.

    Time frame: Up to ~30 months

  5. Time to Treatment Failure (TTF)- BICR

    TTF, defined as the time from the start of study treatment to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause per RECIST, Version 1.1 by BICR was reported.

    Time frame: Up to ~30 months

  6. Overall Survival (OS)

    OS, defined as the interval from the start of study treatment to death from any cause will be reported.

    Time frame: Up to ~30 months

  7. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported.

    Time frame: Up to ~30 months

  8. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who discontinued study treatment due to an AE was reported.

    Time frame: Up to ~11 months

  9. Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule

    Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  10. Cmax of Total Antibody-Q1/3W Dosing Schedule

    Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  11. Cmax of MMAE-Q1/3W Dosing Schedule

    Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  12. Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule

    AUC0-504hrs of Zilovertamab Vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  13. AUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule

    AUC0-504hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  14. AUC0-504hrs of MMAE-Q1/3W Dosing Schedule

    AUC0-504hrs of MMAE by blood collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days

  15. Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 1

    Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  16. Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 1

    Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  17. Cmax of MMAE-Q2/3W Dosing Schedule: Day 1

    Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  18. Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8

    Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days

  19. Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 8

    Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days

  20. Cmax of MMAE-Q2/3W Dosing Schedule: Day 8

    Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days

  21. AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1

    AUC0-168hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  22. AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1

    AUC0-168hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that is not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  23. AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1

    AUC0-168hrs of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days

  24. AUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8

    AUC168-336 hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days

  25. AUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 8

    AUC168-336hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to MMAE. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days

  26. AUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 8

    AUC168-336 of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.

    Time frame: Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days

07

Results

Posted Aug 15, 2024
Limitations and caveats
Study terminated due to business reasons

Participant flow

Participant flow — Overall Study
MilestoneZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Started7032
Completed00
Not completed7032
Withdrew: Study terminated78
Withdrew: Death5418
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject84
Withdrew: Did not agree to follow-up01

Outcome measures

PrimaryObjective Response Rate (ORR)- Blinded Independent Central Review (BICR)

The percentage of participants who achieved a Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) using per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 by BICR was reported.

Time frame:
Up to ~18 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)
Percentage of ParticipantsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Objective Response Rate (ORR)- Blinded Independent Central Review (BICR)1.4 (0.0 to 7.7)0.0 (NA to NA)
SecondaryORR- Investigator Assessed

The percentage of participants who achieved a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST, Version 1.1 by investigator was reported.

Time frame:
Up to ~18 months
Reported as:
Number · Percentage of Participants
ORR- Investigator Assessed
Percentage of ParticipantsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
ORR- Investigator Assessed1.4 (0.0 to 7.7)0.0 (NA to NA)
SecondaryTime to Response (TTR)- BICR

TTR, defined as the time from the start of study treatment to the first documentation of objective tumor response per RECIST, Version 1.1 by BICR was reported.

Time frame:
Up to ~30 months
Reported as:
Mean · Months
Time to Response (TTR)- BICR
MonthsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Time to Response (TTR)- BICR1.9 ± NA—
SecondaryDuration of Response (DOR)- BICR

DOR, defined as the interval from the first documentation of objective tumor response to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.

Time frame:
Up to ~30 months
Reported as:
Median · Months
Duration of Response (DOR)- BICR
MonthsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Duration of Response (DOR)- BICR1 (NA to NA)—
SecondaryProgression-free Survival (PFS)- BICR

PFS, defined as the interval from the start of study treatment to the earlier of the first documentation of disease progression or death from any cause per RECIST, Version 1.1 by BICR was reported.

Time frame:
Up to ~30 months
Reported as:
Median · Months
Progression-free Survival (PFS)- BICR
MonthsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Progression-free Survival (PFS)- BICR2.3 (2.0 to 4.1)1.9 (1.7 to 2.1)
SecondaryTime to Treatment Failure (TTF)- BICR

TTF, defined as the time from the start of study treatment to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause per RECIST, Version 1.1 by BICR was reported.

Time frame:
Up to ~30 months
Reported as:
Median · Months
Time to Treatment Failure (TTF)- BICR
MonthsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Time to Treatment Failure (TTF)- BICR2.2 (1.9 to 4.1)1.9 (1.7 to 2.1)
SecondaryOverall Survival (OS)

OS, defined as the interval from the start of study treatment to death from any cause will be reported.

Time frame:
Up to ~30 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Overall Survival (OS)8.3 (5.2 to 10.3)5.5 (4.4 to 11.0)
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who experienced an AE was reported.

Time frame:
Up to ~30 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Number of Participants Who Experienced an Adverse Event (AE)7032
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who discontinued study treatment due to an AE was reported.

Time frame:
Up to ~11 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
Number of Participants Who Discontinued Study Treatment Due to an AE76
SecondaryMaximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule

Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule
μg/mLZilovertamab Vedotin Q1/3W
Maximum Plasma Concentration (Cmax) of Zilovertamab Vedotin-Q1/3W Dosing Schedule53.4 ± 20.5
SecondaryCmax of Total Antibody-Q1/3W Dosing Schedule

Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of Total Antibody-Q1/3W Dosing Schedule
μg/mLZilovertamab Vedotin Q1/3W
Cmax of Total Antibody-Q1/3W Dosing Schedule51.2 ± 23.3
SecondaryCmax of MMAE-Q1/3W Dosing Schedule

Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of MMAE-Q1/3W Dosing Schedule
μg/mLZilovertamab Vedotin Q1/3W
Cmax of MMAE-Q1/3W Dosing Schedule0.00393 ± 65.7
SecondaryArea Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule

AUC0-504hrs of Zilovertamab Vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule
hr*μg/mLZilovertamab Vedotin Q1/3W
Area Under the Plasma Concentration-time Curve (AUC) 0-504hrs of Zilovertamab Vedotin- Q1/3W Dosing Schedule4030 ± 27.3
SecondaryAUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule

AUC0-504hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule
hr*μg/mLZilovertamab Vedotin Q1/3W
AUC0-504hrs of Total Antibodies-Q1/3W Dosing Schedule6720 ± 28.6
SecondaryAUC0-504hrs of MMAE-Q1/3W Dosing Schedule

AUC0-504hrs of MMAE by blood collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q2/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI); and 2 and 4 hours after EOI)], Day 8 (168 hr), Day 15 (336 hr), and Cycle 2 Day 1 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC0-504hrs of MMAE-Q1/3W Dosing Schedule
hr*μg/mLZilovertamab Vedotin Q1/3W
AUC0-504hrs of MMAE-Q1/3W Dosing Schedule0.828 ± 58.1
SecondaryCmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 1

Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 1
μg/mLZilovertamab Vedotin Q2/3W
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 128.6 ± 40.8
SecondaryCmax of Total Antibody-Q2/3W Dosing Schedule: Day 1

Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 1
μg/mLZilovertamab Vedotin Q2/3W
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 126.2 ± 39.8
SecondaryCmax of MMAE-Q2/3W Dosing Schedule: Day 1

Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of MMAE-Q2/3W Dosing Schedule: Day 1
μg/mLZilovertamab Vedotin Q2/3W
Cmax of MMAE-Q2/3W Dosing Schedule: Day 1.00121 ± 332.3
SecondaryCmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8

Cmax of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8
μg/mLZilovertamab Vedotin Q2/3W
Cmax of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 835.0 ± 90.3
SecondaryCmax of Total Antibody-Q2/3W Dosing Schedule: Day 8

Cmax of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 8
μg/mLZilovertamab Vedotin Q2/3W
Cmax of Total Antibody-Q2/3W Dosing Schedule: Day 839.1 ± 73.7
SecondaryCmax of MMAE-Q2/3W Dosing Schedule: Day 8

Cmax of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168 hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · μg/mL
Cmax of MMAE-Q2/3W Dosing Schedule: Day 8
μg/mLZilovertamab Vedotin Q2/3W
Cmax of MMAE-Q2/3W Dosing Schedule: Day 80.00289 ± 90.9
SecondaryAUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1

AUC0-168hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 1
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC0-168hrs of Zilovertamab Vedotin -Q2/3W Dosing Schedule: Day 12070 ± 26.1
SecondaryAUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1

AUC0-168hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that is not conjugated to monomethyl auristatin E (MMAE). Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 1
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC0-168hrs of Total Antibody-Q2/3W Dosing Schedule: Day 12730 ± 25.0
SecondaryAUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1

AUC0-168hrs of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose were reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 1 [(predose; end of infusion (EOI)], Day 8 (predose); each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 1
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC0-168 hr of MMAE-Q2/3W Dosing Schedule: Day 10.202 ± 101.2
SecondaryAUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8

AUC168-336 hrs of zilovertamab vedotin determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 8
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC168-336hrs of Zilovertamab Vedotin-Q2/3W Dosing Schedule: Day 82900 ± 66.0
SecondaryAUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 8

AUC168-336hrs of total antibody determined by blood samples collected pre-dose and at designated timepoints post-dose was reported. Total Antibody was defined as total zilovertamab vedotin plus any antibody that was not conjugated to MMAE. Per protocol the Zilovertamab vedotin Q1/3W Dosing Group was not included in this analysis.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 8
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC168-336 Hrs of Total Antibody-Q2/3W Dosing Schedule: Day 85890 ± 48.1
SecondaryAUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 8

AUC168-336 of MMAE determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.

Time frame:
Day 8 [(predose; end of infusion (EOI)], Day 15 (168hr), Cycle 2 Day 1 Predose; each cycle=21 days
Reported as:
Geometric mean · hr*μg/mL
AUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 8
hr*μg/mLZilovertamab Vedotin Q2/3W
AUC168-336 hr of MMAE-Q2/3W Dosing Schedule: Day 80.596 ± 103.3

Adverse events

Collected over Up to 30 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilovertamab Vedotin Q1/3W54/70 (77.1%)29/70 (41.4%)66/70 (94.3%)
Zilovertamab Vedotin Q2/3W18/32 (56.3%)16/32 (50%)30/32 (93.8%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
DyspnoeaRespiratory, thoracic and mediastinal disorders5/701/32
FatigueGeneral disorders0/702/32
Neutrophil count decreasedInvestigations2/702/32
PyrexiaGeneral disorders4/701/32
PneumoniaInfections and infestations3/700/32
Abdominal distensionGastrointestinal disorders0/701/32
Small intestinal obstructionGastrointestinal disorders0/701/32
VomitingGastrointestinal disorders1/701/32
PainGeneral disorders0/701/32
Sudden deathGeneral disorders0/701/32
Most frequent other events
Showing 10 of 64
Most frequent other events
EventZilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3W
NauseaGastrointestinal disorders23/7016/32
FatigueGeneral disorders25/7014/32
Aspartate aminotransferase increasedInvestigations23/703/32
DiarrhoeaGastrointestinal disorders21/706/32
VomitingGastrointestinal disorders14/709/32
Decreased appetiteMetabolism and nutrition disorders18/704/32
Blood potassium decreasedInvestigations15/708/32
Haemoglobin decreasedInvestigations15/708/32
AlopeciaSkin and subcutaneous tissue disorders15/708/32
DyspnoeaRespiratory, thoracic and mediastinal disorders10/707/32

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3WTotal
Mean58.7 ± 11.7962.7 ± 11.6260.0 ± 11.82
Sex: Female, Male
Sex: Female, Male(Participants)Zilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3WTotal
Female642488
Male6814
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3WTotal
Hispanic or Latino617
Not Hispanic or Latino632992
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Zilovertamab Vedotin Q1/3WZilovertamab Vedotin Q2/3WTotal
American Indian or Alaska Native101
Asian11112
Native Hawaiian or Other Pacific Islander000
Black or African American718
White462975
More than one race000
Unknown or Not Reported516
08

Study locations

14 sites
  • Memorial Regional Hospital-Memorial Cancer Institute ( Site 0005)
    Hollywood, Florida 33021, United States
  • AdventHealth Orlando ( Site 0003)
    Orlando, Florida 32804, United States
  • Massachusetts General Hospital ( Site 0017)
    Boston, Massachusetts 02114, United States
  • John Theurer Cancer Center at Hackensack University Med Ctr ( Site 0002)
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center ( Site 0007)
    New York, New York 10021, United States
  • MD Anderson ( Site 0001)
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at San Antonio ( Site 0004)
    San Antonio, Texas 78229, United States
  • Swedish Medical Center ( Site 0008)
    Seattle, Washington 98104, United States
  • Cross Cancer Institute ( Site 0012)
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer Vancouver ( Site 0011)
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Cancer Centre ( Site 0006)
    Toronto, Ontario M5G 2M9, Canada
  • Centre intégré de cancérologie du CHUM ( Site 0016)
    Montreal, Quebec H2X 0A9, Canada
  • Jewish General Hospital ( Site 0013)
    Montreal, Quebec H3T 1E2, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
    Québec, Quebec G1J 1Z4, Canada
09

References and documents

Publications

  • Meric-Bernstam F, Gutierrez M, Sanz-Garcia E, Villa D, Zhang J, Friedmann J, Yan F, Socinski MA, Sarantopoulos J, Raez LE, Chu QS, Chenard-Poirier M, Chatterjee MS, Ren H, Liu Q, Levine DA, Jhaveri KL. Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Res Commun. 2025 Sep 1;5(9):1664-1673. doi: 10.1158/2767-9764.CRC-25-0019. PubMed 40762544 ↗
  • Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pd

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jun 2023, 32 months.

Results were first posted in Aug 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2020
First posted
Aug 7, 2020
StartActual
Oct 7, 2020
Primary completionActual
Jun 12, 2023
CompletionActual
Jun 12, 2023
Results first posted
Aug 15, 2024
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04504916
Responsible party
Sponsor
First posted
Aug 7, 2020
Start date
Oct 7, 2020
Primary completion
Jun 12, 2023
Completion
Jun 12, 2023
Results posted
Aug 15, 2024
Last update
Nov 10, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilovertamab vedotin

Start the discussion